Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m 2 ) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m 2 ) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m2 in Japan and Europe. Although lower doses are established alternatives based on randomized controlled trial...

Authors:Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Takeshi Seto, Shoko Tsukube and Kazuhiro Suzuki

Citation:BMC Cancer 2020 20:649

Content type:Research article

 

Published on: 13 July 2020

• ViewFull Text
 
• ViewPDF